Business
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine release syndrome observed in the ongoing RAINIER trial: ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials","length":101,"tagName":"p"},{"type":"text","content":"Mipletamig triplet combination continues to outperform standard doublet benchmark","length":81,"tagName":"p"},{"type":"text","content":"No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML","length":123,"tagName":"p"},{"type":"text","content":"Cohort 2 enrollment is complete, and Cohort 3 is now enrolling","length":62,"tagName":"p"},{"type":"text","content":"SEATTLE, WA / ACCESS Newswire / May 15, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter ended March 31, 2025, and provided an update on the ongoing mipletamig clinical trial.","length":393,"tagName":"p"},{"type":"text","content":"Business Update"The latest outcomes from the RAINIER trial-remissions that were achieved rapidly and with no reported cytokine release syndrome-underscore the strength of our approach and the potential of mipletamig to redefine frontline AML treatment. With each milestone, we are not only validating the safety and efficacy of our drug, but moving closer to changing the standard of care for patients who have long had limited options. We remain focused on advancing the trial and look forward to sharing further clinical updates in the months ahead. This is more than progress-it's momentum toward a new era in frontline AML care," said Marvin White, President and CEO of Aptevo.","length":696,"tagName":"p"},{"type":"text","content":"Mipletamig Data HighlightsEnrollment continues in the RAINIER dose optimization trial. This is a Phase 1b/2 study evaluating mipletamig in combination with venetoclax and azacitidine, the standard of care for frontline acute myeloid leukemia (AML) patients who are unfit to receive intensive high dose chemotherapy. Cohort 2 enrollment is now complete, and Cohort 3 is now open and enrolling.","length":393,"tagName":"p"},{"type":"text","content":"Mipletamig has been evaluated in almost 100 patients across three clinical studies, thus far, in both combination and monotherapy set...